DrugPatentWatch Database Preview
NERLYNX Drug Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
Which patents cover Nerlynx, and what generic alternatives are available?
Nerlynx is a drug marketed by Puma Biotech and is included in one NDA. There are nine patents protecting this drug.
This drug has one hundred and eleven patent family members in twenty-three countries.
The generic ingredient in NERLYNX is neratinib maleate. Additional details are available on the neratinib maleate profile page.
US ANDA Litigation and Generic Entry Outlook for Nerlynx
Nerlynx will be eligible for patent challenges on July 17th, 2021. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 29th, 2025. This may change due to patent challenges or generic licensing.
Summary for NERLYNX
| International Patents: | 111 |
| US Patents: | 9 |
| Applicants: | 1 |
| NDAs: | 1 |
| Bulk Api Vendors: | 83 |
| Clinical Trials: | 3 |
| Patent Applications: | 131 |
| Drug Prices: | Drug price information for NERLYNX |
| DailyMed Link: | NERLYNX at DailyMed |
Generic Entry Opportunity Date for NERLYNX
Generic Entry Date for NERLYNX*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for NERLYNX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Puma Biotechnology, Inc. | Phase 1/Phase 2 |
| Virginia Commonwealth University | Phase 1/Phase 2 |
| NSABP Foundation Inc | Phase 2 |
Synonyms for NERLYNX
| (2e)-n-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide |
| (2e)-n-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide neratinib |
| (2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide |
| (2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide;HKI-272 |
| (E)-N-(4-((3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide |
| (E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylami |
| (E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide |
| (E)-N-[4-[3-chloro-4-(2-pyridylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolyl]-4-(dimethylamino)but-2-enamide |
| 2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)- |
| 387N096 |
| 4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide |
| 698387-09-6 |
| 698387-09-6, HKI272, HKI 272, HKI-272, |
| 736156-77-7 |
| A25338 |
| AB0008022 |
| ABP000871 |
| AC-25073 |
| AK170454 |
| AKOS005146340 |
| AKOS025149637 |
| AN-546 |
| AOB87125 |
| AS-16279 |
| BC256322 |
| BCP9000984 |
| BCPP000151 |
| BDBM50161957 |
| BIFK0031 |
| BRD-K85606544-001-01-8 |
| C30H29ClN6O3 |
| cc-32 |
| CDP-820 |
| CHEMBL180022 |
| D08950 |
| DB11828 |
| DTXSID70220132 |
| EX-A062 |
| GTPL5686 |
| HKI 272 |
| HKI-272 |
| HY-32721 |
| I06-2375 |
| JJH94R3PWB |
| JSPY-st000262 |
| KB-58129 |
| MolPort-006-069-389 |
| N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide |
| NCGC00241101-01 |
| NCGC00241101-03 |
| Neratinib |
| Neratinib - HKI-272 |
| Neratinib (HKI-272) |
| Neratinib (USAN/INN) |
| Neratinib [USAN:INN] |
| Neratinib HKI 272 |
| Neratinib(HKI-272) |
| Neratinib(HKI-272)/HKI272 |
| PB 272 |
| PB-272 |
| PubChem22399 |
| Q-101402 |
| QCR-104 |
| RL04677 |
| s2150 |
| SB16595 |
| SC-28031 |
| SCHEMBL571762 |
| SCHEMBL571763 |
| SYN1140 |
| Tube708 |
| UNII-JJH94R3PWB |
| WAY-179272 |
| WAY-179272-B |
| X2638 |
| Z-3202 |
| ZINC3916214 |
| ZX-AFC000299 |
US Patents and Regulatory Information for NERLYNX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for NERLYNX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for NERLYNX
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Denmark | 2498756 | Start Trial |
| South Korea | 20160136474 | Start Trial |
| Israel | 247609 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
